Evidence mapPaperPMID 41495639Full record

ArticleBMC bioinformatics2026

Hgtsynergy: a transfer learning method for predicting anticancer synergistic drug combinations based on a drug-drug interaction heterogeneous graph.

Xiaowen Wang, Yanming Huang, Hongming Zhu, Dongsheng Mao, Xiaoli Zhu, Qin Liu

Abstract read
In one paragraph

Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaowen Wang *School of Computer Science and Technology, Tongji University, Shanghai, 201804, China.
Yanming Huang *School of Computer Science and Technology, Tongji University, Shanghai, 201804, China.
Hongming ZhuSchool of Computer Science and Technology, Tongji University, Shanghai, 201804, China.
Dongsheng MaoDepartment of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Xiaoli ZhuDepartment of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China. xiaolizhu@tongji.edu.cn.ORCID http://orcid.org/0000-0001-5497-4538
Qin LiuSchool of Computer Science and Technology, Tongji University, Shanghai, 201804, China. qin.liu@tongji.edu.cn.ORCID http://orcid.org/0000-0002-9352-1694

Funding

National Natural Science Foundation of China 62576250Tongji University Medicine-X Interdisciplinary Research Initiative 2025-0553-ZD-03
6 · The paper itself

Abstract

backgroundDrug combination therapy often outperforms monotherapy in cancer treatment, but the vast number of available drugs makes manual screening for synergistic combinations costly. Computational methods, especially deep learning, can reduce the search space by predicting likely synergistic drug combinations. Recent studies have improved drug synergy prediction by modeling associations among different biological entities, but drug-drug interactions have not been fully leveraged in this scenario, which motivated the work presented in this paper.

methodsThis paper proposes a deep learning method named HGTSynergy to predict synergistic drug combinations, which employs a heterogeneous graph attention network and a tailored task to capture complex latent patterns in the drug network as prior knowledge. The learned knowledge is then transferred through a transfer learning framework to the downstream task of predicting drug synergy scores, effectively enhancing predictive performance.

resultsA five-fold nested cross-validation is employed to train HGTSynergy. In the synergy regression task, HGTSynergy outperforms seven deep learning methods, achieving a mean squared error of 222.83, root mean squared error of 14.91, and Pearson correlation coefficient of 0.75. For the synergy classification task, it also surpasses other methods with an area under the receiver operating characteristic curve of 0.90, area under the precision-recall curve of 0.63, accuracy of 0.94, precision of 0.72, and Cohen's Kappa of 0.52. The ablation study verifies that the heterogeneous graph attention network and the transfer learning framework both have a positive effect on prediction performance. Moreover, a series of analyses demonstrates that the proposed method exhibits strong generalization performance and interpretability. The case study further validates its consistency with prior research.

conclusionsThis study suggests that drug synergy prediction can be improved by comprehensively modeling diverse drug-drug interaction types and leveraging transfer learning to extract prior knowledge from them. The ability of HGTSynergy to discover new anticancer synergistic drug combinations outperforms other state-of-the-art methods. HGTSynergy promises to be a powerful tool to pre-screen anticancer synergistic drug combinations.

Indexed as

Antineoplastic AgentsComputational BiologyDeep LearningDrug SynergismDrug InteractionsHumansNeoplasmsAntineoplastic AgentsDeep learningDrug-drug interactionDrug synergy predictionHeterogeneous graph attention networkTransfer learning

Identifiers

PMID41495639
PMCPMC12870253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.